Eli Lilly is moving to expand its use of artificial intelligence as it searches for its next big growth engine after the surge in GLP-1 medicines for diabetes and obesity. The Indianapolis-based drugmaker is positioning AI across research and development to speed discovery, sharpen clinical trial design, and prepare for tighter competition in weight management drugs.
“To find its next success cycle after GLP-1s, Lilly’s turning to AI investments.”
The shift signals a push to lock in gains made through blockbuster weight-loss treatments while laying groundwork for future drugs. It also reflects a broader race among large pharmaceutical firms to apply data-driven tools to cut costs and time in development.
Background: From GLP-1 Momentum to What Comes Next
GLP-1 therapies have transformed Lilly’s growth profile, with demand outpacing supply at times and reshaping the market for diabetes and obesity care. Rival Novo Nordisk has seen similar momentum, intensifying the contest in efficacy, dosing, and access. Analysts say that while demand remains strong, investors are already asking what will fuel revenue in the next decade.
AI has become a central part of that answer across the industry. Large drugmakers are striking deals with specialized AI groups and building internal platforms to model protein structures, predict drug-target interactions, and screen vast chemical libraries with fewer lab experiments. In early 2024, Alphabet’s Isomorphic Labs announced partnerships with multiple companies, including Lilly, to apply its models to small-molecule design. Such agreements show how external alliances can accelerate internal pipelines.
Why AI Now
Drug development remains slow and costly, with high rates of failure. AI tools promise faster hit discovery, better selection of drug candidates, and smarter trial planning. By triaging ideas earlier, companies can reduce late-stage setbacks. For Lilly, that could help diversify revenue beyond GLP-1s and spread risk across oncology, immunology, neurology, and cardiometabolic disease.
- Faster identification of promising compounds
- Improved patient selection and trial endpoints
- Better manufacturing forecasts and supply planning
These gains can shorten timelines and improve the odds that a candidate reaches approval.
Inside the Investment Strategy
Lilly’s approach appears two-pronged: build internal data infrastructure and partner where outside technology can speed results. Internal efforts often include data lakes that combine chemistry, biology, and clinical data; model-sharing across research units; and training for scientists to use AI tools effectively.
External collaborations offer access to specialized algorithms, high-quality training data, and expert teams. Deal structures typically include research funding, milestone payments, and royalties on approved drugs. While specific financial terms vary, the goal is consistent: translate computational predictions into trial-ready candidates faster than traditional methods allow.
Benefits and Limits
AI can spot patterns that humans miss and simulate experiments at scale, but it is not a cure-all. Models are only as good as the data they ingest. Biases in training sets can mislead results. Wet-lab validation, rigorous toxicology, and clinical evidence remain essential. Regulators will still expect clear proof of safety and efficacy.
Investors will watch for concrete milestones, such as a candidate entering the clinic that was discovered primarily through AI workflows. Cost savings are another test. Reduced cycle times or smaller, smarter trials would show that the tools are paying off.
Industry Impact and What to Watch
If AI-enabled discovery shortens timelines by even a modest fraction, the effect on pipelines could be significant. More shots on goal may lead to more approvals. Competition among AI vendors may also lower costs and improve quality, benefiting early adopters.
Key signals in the months ahead include:
- New AI-originated programs entering Phase 1
- Evidence that trial enrollment speeds up using model-guided selection
- Manufacturing and supply gains as forecasting models mature
Competitors are making similar moves, which may raise the bar for speed and data quality across the sector.
Lilly’s bet on AI suggests a clear message: the company plans to convert its GLP-1 windfall into longer-term innovation. The next steps will be measured in pipeline breadth, trial efficiency, and approvals. For patients, faster development could mean more treatment options across major diseases. For investors, the focus will be on proof that AI is not just a tool, but a driver of sustainable growth.
